E-ONLY ARTICLES
Free Access
Annual clinical updates in hematological malignancies: a continuing medical education series
First published: 25 October 2017
Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management. DOI: 10.1002/ajh.24797
The wrong data was presented in Tables I-2. The corrected Tables I-2 are reprinted below in its entirety.
All the authors of the manuscript have been informed of the changes and have agreed to the publication of an erratum. We apologize for any inconvenience that this error might have caused.
DOI: 10.1002/ajh. 24907
Correspondence to:
Julie M. Vose, Division of Hematology/Oncology, University of Nebraska Medical Center, Omaha, Nebraska 68198-7680
Email: [email protected]
| 0.03535x age (y) |
| + 0.6978 (if ECOG performance status > 1) |
| + 1.367 X log 10 (LDH/ULN LDH) |
| + 0.9393 X log10(white blood cells per 106 L) |
| Points | Age, years | ECOG PS | LDH/ULN LDH | WBC, 109/L |
| 0 | < 50 | 0–1 | < 0.67 | < 6.700 |
| 1 | 50–59 | — | 0.67 – 0.99 | 6.700 – 9.999 |
| 2 | 60–69 | 2–4 | 1.00 – 1.49 | 10.000 – 14.999 |
| 3 | ≥ 70 | — | ≥ 1.50 | ≥ 15.000 |
- Erratum in “Hoster et al. A new prognostic index (MIPI) for patients with advanced stage mantle cell lymphoma. Blood. 2008;111:558–565.” Blood 2008;111:5761
